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1. Introduction
Cancer will become a major cause of morbidity and mortality in the next decades. It is estimated
that the global cancer rate may increase by 75 %, with predicted 22.2 million new cases by 2030
compared with 12.7 million cases in 2008 [1]. The scientific community has made tremendous
efforts to develop new therapies to deal effectively with this growing problem. As the recent
advances in cancer therapy are improving the cancer patient survival, the toxic effects
promoted by anticancer agents have a higher potential impact on long-term outcomes.
Anticancer agents are known to cause severe toxic effects that should be anticipated and
carefully monitored. Therapeutic regimens targeting the cell cycle also affect the prolifera‐
tion of normal cells, such as blood cells in the bone marrow, cells in the digestive tract and
hair  follicles,  resulting  in  neutropenia,  hair  loss,  and  gut  toxicity.  The  side  effects  ob‐
served are dependent on the type of therapy, but they are generally reversible and disappear
after  the end of  the treatment.  However,  some anticancer agents  may also affect,  some‐
times in a permanent manner, the function of vital organs, such as the heart, kidney, liver
and the nervous system. Some of these effects may develop during or shortly after treatment,
or may only become apparent a long period after completion of the treatment; if this delay
is long enough, it may correspond to the time of progression free survival and affect the
benefit-risk balance [2, 3].
Both the liver and kidneys are vulnerable to the toxic effects of cancer therapy and also to the
direct impact of cancer itself. The liver has a great capacity to resist injury and to regenerate,
but this capacity also makes it susceptible to anticancer drugs toxicity [2]. Indeed, the liver
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injury induced by anticancer drugs is a significant cause of morbidity and mortality. However,
most of these reactions are idiosyncratic and are not typically dose-dependent [2, 4]. Diagnos‐
ing liver damage due to anticancer agents is particularly challenging because competing
etiologies, such as hepatotoxicity due to the intake of other medications, opportunistic
infections, radiation therapy, and pre-existing liver disease, are frequent and greatly affect the
host’s susceptibility to liver injury [2, 4]. The major mechanisms underlying chemotherapy-
related hepatotoxicity are based on the production of reactive metabolites, immunological
injury, or mitochondrial dysfunction [4]. On the other hand, the spectrum of cancer-associated
renal disease has changed in the last decades, mainly due to the introduction of new chemo‐
radiotherapy regimens. Nevertheless, renal failure remains an important complication of
cancer treatment [5, 6]. Considering that drugs are primarily metabolized in the liver and
excreted by the kidneys, hepatic and renal impairment can have an unpredictable impact on
the metabolism and clearance of drugs that may ultimately affect the treatment outcome and
toxicity.
In addition, cardiotoxicity is a common complication not only related to conventional cancer
therapy, such as anthracyclines, but also to new antitumoral targeted therapy, such as
trastuzumab. Due to the increasing number of patients treated with these agents, the incidence
of cardiotoxicity is continuously growing and strongly affecting the patients’ quality of life
and overall survival, regardless of the oncologic prognosis [3]. Also, peripheral neuropathy is
reported by 30-40 % of the patients and is one of the major reasons responsible for cessation
of treatment [7]. Certain structural and functional features of peripheral nervous system make
it more vulnerable to the action of anticancer drugs, namely the absence of a vascular barrier
and of lymph drainage [7]. Furthermore, mammalian nerves are more susceptible to oxidative
stress because of their high content of phospholipids, mitochondria rich axoplasm and weak
cellular antioxidant defenses. Moreover, the enhanced free radical production promoted by
anticancer drugs causes physical damage to neurons [7].
A thorough understanding of the mechanisms of injury is therefore a matter of great impor‐
tance since it may contribute to detect toxic mechanisms at an early stage of drug development
and, importantly, it can contribute to develop strategies aiming to minimize the toxicity.
Mitochondrial dysfunction often underlies drug-induced toxicity and the works published
over the last years point out that some of the severe adverse effects promoted by anticancer
agents involve the targeting of mitochondria [8-11]. The heart, the kidneys, and the central
nervous system, which have high energetic demands and are heavily dependent on oxidative
phosphorylation, are more prone to the impact of mitochondrial damage. On the other hand,
considering the exposure to high concentrations of drugs, the liver is another common organ
showing mitochondrial dysfunction [12].
This chapter aims to provide an overview of the mechanisms of mitochondrial dysfunction
induced by anticancer drugs and their involvement in several adverse effects, and particularly
liver damage. Finally, possible combinations of therapeutic drugs to minimize the mitochon‐
drial dysfunction promoted by these agents are discussed.
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2. Methods
We searched literature published in English language included in PubMed for the period of
1970 to 2014. The main keywords searched were “mitochondrial dysfunction”, “anticancer
drugs and toxicity” and “tissue failure”. The remaining papers were found in the reference list
of the searched publications.
3. Anticancer drugs-induced tissue injury: The role of mitochondrial
dysfunction
Mitochondria are dynamic and multifunctional cytoplasmic organelles, which possess a
double membrane: an outer membrane (OMM) that is essentially permeable to ions and solutes
up to 14 kDa, and an inner membrane (IMM), which is folded, forming the cristae, which is
impermeable to ions and polar molecules. In the IMM are located several transporters,
including the ATP/ADP and the aspartate/malate transporters, among others that regulate the
movements of molecules across the IMM, and also the multisubunit complexes involved in
the oxidative phosphorylation. Between the OMM and the IMM is located the intermembrane
space (IMS), whereas the space enclosed by the IMM is the matrix (Fig.1). The IMS contains
proteins such as the adenylate kinase and the creatine kinase (CK), as well as the cytochrome
c and the apoptosis-inducing factor (AIF), which translocate to the cytoplasm during the
apoptotic process, and other proteins involved in cellular metabolism. The proteins involved
in the Krebs cycle, in the fatty acid oxidation, as well as in the synthesis of the heme and
steroids, are located in the matrix [8, 9, 12, 13]. The mitochondrial matrix also contains the
mitochondrial DNA (mtDNA). Thus, mitochondria are not only responsible for the synthesis
of most of the ATP produced in the cell, but they also play a role in the fatty acid oxidation,
the synthesis of the heme, steroids, and polypeptides involved in energy generation, as well
as in calcium regulation and cell death. Therefore, taken in account the multitude of essential
functions of mitochondria in cells, it is expected that their dysfunction might promote tissue
failure, as described below.
3.1. Disturbance of mitochondrial energy production
The NADH and FADH2 generated in metabolic pathways, including glycolysis, fatty acid
oxidation and Krebs cycle are oxidized by complexes I and II of the mitochondrial electron
transport  chain,  respectively.  The  electrons  liberated  are  then  passed  to  ubiquinone
(coenzyme Q) that shuttles electrons to complex III, where it is oxidized; the electrons are
then passed to complex IV through cytochrome c.  The electrons carried by cytochrome c
are used by complex IV to reduce molecular oxygen to water (Fig.1) [8, 14]. According to
Peter  Mitchell’s  Chemiosmotic  Theory,  complexes  I,  III  and IV are  redox-driven proton
pumps that harness the energy derived from oxidation-reduction reactions to pump protons
into the IMS, in parallel to the electron transfer, creating the electrochemical proton gradient
(proton motive force) (ΔµH+), which is comprised of two components: a pH gradient (ΔpH)
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and a membrane potential (ΔΨ) (Fig. 1). The complex V (ATP synthase), which consists of
the F1 subunit, a soluble portion located in the mitochondrial matrix, and the Fo subunit,
bound to the IMM, uses the electrical component ΔΨ to phosphorylate ADP to ATP. Thus,
the oxidative phosphorylation is coupled to the ATP requirements and the electron flow
along the electron transport chain only occurs when the synthesis of ATP is required. The
IMM  impermeability  ensures  that  the  proton  pumping  along  the  respiratory  chain  is
coupled to ATP synthesis [8, 12, 14].
Figure 1. Structure of mitochondria and main mechanisms by which anticancer agents affect mitochondrial functions.
Drugs can compromise mitochondrial bioenergetic functions by interfering with the generation system of ΔµH+, by
dissipating the transmembrane proton gradient and by directly affecting the complex V or the substrate transporters.
Drugs can also trigger or inhibit the mitochondrial permeability transition (MPT) by interfering with the proteins that
compose or regulate the MPT or by modulating the critical factors to its onset, which may ultimately lead to cell death.
Other drugs induce changes in the redox regulation of mitochondrial functions, promoting several deleterious events,
including the interference with oxidative phosphorylation, nutrient oxidation and MPT. Drugs can also damage the
mtDNA and, indirectly, compromise the ATP synthesis and favor the production of ROS (ANT, adenine nucleotide
translocase; CyPD, cyclophilin-D; Cytc, cytochrome c; mnSOD, manganese superoxide dismutase; mtDNA, mitochon‐
drial DNA; PiC, phosphate carrier; Prx, glutathione peroxidase; Q, coenzyme Q).
Xenobiotics can affect mitochondrial bioenergetic functions either by interfering with the
generation system of ΔµH+or by causing the dissipation of the transmembrane proton gradient,
as well as by affecting directly the F1Fo ATPase and the substrate transporters, including the
adenine nucleotide translocase (ANT) and the phosphate–hydrogen co-transporter (phos‐
phate carrier) (Fig.1) [14].
In fact, the inhibition of the electron transport chain by drugs may not only lead to ATP
depletion, but also hinders the reoxidation of NADH and FADH2 into NAD+and FAD,
respectively, which are required for the activity of several dehydrogenases of the Krebs cycle
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and the mitochondrial β-oxidation [15, 16]. In addition, the inhibition of the electron transport
chain favors the accumulation of electrons in the electron transport system complexes that can
escape and directly react with oxygen to form the superoxide anion radical [17]. The excessive
reactive oxygen species (ROS) production can promote several deleterious events (described
in more detail in section 3.3), but it is noteworthy that, in this context, both lipid accumulation
and lipid peroxidation are favored [15, 16].
On the other hand, drugs can compromise the impermeability of the IMM to protons and
dissipate the proton gradient impairing the production of ATP. The IMM impermeability can
be surpassed by drugs that either disrupt the mitochondrial membranes or act as ionophores,
uncouplers of the oxidative phosphorylation and inducers of the mitochondrial permeability
transition (MPT) [12-14]. Moreover, drugs that interfere with the basic components of the
phosphorylative system can also impair the production of ATP. These different effects on
mitochondria induce changes in cellular bioenergetics, one of the key hallmarks in tissues.
3.2. Mitochondria in Ca2+homeostasis: MPT-dependent cell death
Besides serving as the cells’ primary energy source, mitochondria are implicated in the
maintenance of calcium homeostasis through calcium uptake and release pathways. The rise
of mitochondrial matrix free calcium concentration in the presence of a variety of sensitizing
factors can lead to the opening of the MPT pore that may serve either the purpose of providing
a fast calcium release or can convey both apoptotic and necrotic death signals.
MPT can be defined as an increase in the IMM permeability to solutes with molecular masses
up to 1 500 Da, due to the opening of a voltage and calcium-dependent, cyclosporine A (CyA)-
sensitive channel [18].
The molecular identity of the MPT pore is still under debate [19] (Fig. 1). Cyclophilin-D is the
binding site for CyA, the golden standard of MPT inhibitors, and among the several compo‐
nents that have been proposed to play a role on MPT, cyclophilin-D is probably the most
consensual. The ANT and the voltage-dependent anion channel (VDAC) were also considered
key components of the MPT pore complex for many years. Knockout mice devoid of cyclo‐
philin-D are resistant to necrosis promoted by ROS and calcium overload and the mitochondria
isolated from the liver, heart and brain of these animals are resistant to MPT in vitro [20, 21].
Although these results support a central role for cyclophilin-D, MPT can occur even in the
absence of cyclophilin-D if the calcium concentration is high enough [22]. Likewise, MPT can
occur in mitochondria lacking ANT, although a higher concentration of calcium is required
[23] and, therefore, the ANT is now considered a regulatory component of the MPT pore, rather
than a structural one. Similar studies have excluded the VDAC as an essential component of
MPT pore megacomplex [24].
The phosphate carrier was also proposed to play a key role in MPT [25], but a later study
demonstrated that the reduction of phosphate carrier protein expression does not affect the
MPT [26]. A more recent work suggested that the MPT pore complex is composed of ATP
synthase dimers and pointed out that cyclophilin-D binds the lateral stalk of the ATP synthase
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at the same site as benzodiazepine 423, increasing the sensitivity to calcium [27]. However, the
composition of MPT still remains a contentious issue.
Besides the calcium concentration in the matrix, the level of oxidative stress is possibly the
most critical factor regulating MPT pore opening. Indeed, both the ANT and cyclophilin D
were shown to be modulated by S-oxidation reactions [28-29]. However, other factors may
contribute as well: the depletion of adenine nucleotides and high concentrations of phosphate
increase the sensitivity of MPT to calcium, while a low pH and a high (negative) ΔΨ inhibit
MPT pore opening [30].
Drugs can trigger MPT either by interfering with the proteins that compose or regulate the
MPT or by modulating the critical factors to its onset (Fig.1) [8]. As a consequence of MPT pore
opening, the IMM loses its impermeability to protons, which allows the movement of solutes
between the matrix and the cytosol, the dysregulation of cellular ionic homeostasis and the
dissipation of ΔµH+. Moreover, since the protein concentration is higher in the matrix, a high
osmotic pressure is generated and may lead to mitochondrial swelling, rupture of OMM, and
loss of proapoptotic proteins that may trigger the apoptotic pathway in the cytoplasm [30,
31]. These events, together with the bioenergetic failure and the redox catastrophe, can
culminate in cell death; if there are no sufficient levels of ATP, necrotic death may predominate
over apoptosis [32]. Thus, depending on the cell type involved, different pathological condi‐
tions can occur as consequence of MPT induction.
3.3. Changes in redox regulation of mitochondrial functions
During the transfer of electrons along the electron transport chain to oxygen, and particularly
at complexes I and III, some of these electrons escape and directly react with oxygen. The
univalent reduction of oxygen generates the superoxide anion radical, which is then dismu‐
tated by the mitochondrial manganese superoxide dismutase into hydrogen peroxide, a key
ROS signaling molecule due to its longer half-life and capacity to diffuse through membranes.
The hydrogen peroxide is detoxified into water by the mitochondrial glutathione peroxidase
and hence, in normal circumstances, most of the ROS generated by the electron transport chain
are neutralized by the mitochondrial antioxidant defenses (Fig.1) [17]. The accumulation of
hydrogen peroxide can promote the oxidation of thiolic groups, irreversibly deactivating the
protein; likewise, the superoxide anion disassembles Fe–S clusters in several Krebs cycle
enzymes and in respiratory complexes, and can combine with nitric oxide to form the highly
toxic peroxynitrite. In addition, high levels of ROS can lead to the production of hydroxyl
radical, which indiscriminately oxidizes biological macromolecules [33]. Other sources that
can contribute to the total mitochondrial ROS include 2-oxoglutarate dehydrogenase, pyruvate
dehydrogenase, dihydroorotate dehydrogenase, sn-glycerol-3-phosphate dehydrogenase,
electron transfer flavoprotein:ubiquinol oxidoreductase, p66shc/Cytochrome C, Mia40p/
Erv1p, and complex II [33]. When maintained within a certain concentration range, ROS act
as important signaling molecules, contributing to the redox balance, which regulates the
functions that assist the normal cellular physiology [33]. However, the excessive formation of
ROS can promote a series of deleterious events that deregulate key mitochondrial functions,
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including oxidative phosphorylation, nutrient oxidation and MPT, which may ultimately lead
to cell death, tissue failure and have also a key role in disease pathogenesis [33].
3.4. Mitochondrial DNA damage
The mtDNA, maternally inherited, encodes 13 polypeptides that are subunits of the complexes
I, III, IV and V, which are synthesized in mitochondrial ribosomes. The majority of the other
mitochondrial proteins, including the subunits of complex II, are encoded by nuclear DNA,
and imported into mitochondria after synthesis on cytosolic ribosomes [8-10].
The mtDNA is particularly vulnerable to the action of drugs, as it lacks histones, similarly to
the bacterial DNA. Furthermore, the DNA repair mechanisms are less efficient that those of
nuclear DNA. Therefore, and considering the proximity to the sites where ROS are routinely
generated, the frequency of mtDNA mutation is much higher than that of nuclear DNA [13].
Mutations of mtDNA can seriously damage the respiratory chain as most of the polypeptides
that form the respiratory chain complexes are encoded by mtDNA. As discussed in section
3.1., the impairment of the respiratory chain decreases the ATP synthesis capacity and
enhances the production of ROS, which in turn will promote oxidative damage on several
biomolecules, including the mtDNA itself, creating a vicious cycle that further enhances the
insult [34].
4. Anticancer drugs impair mitochondria functions: relevance to tissue
failure
In the last decades a large number of anticancer drugs have been reported to induce tissue
failure by promoting changes in essential functions of mitochondria. The extent and type of
mechanisms underlying the anticancer drug-induced mitochondrial dysfunctions are tissue-
dependent and responsible for most of the idiosyncratic adverse drug responses.
In this section, we discuss some examples of the prominent members of different groups of
anticancer drugs with evidences for the involvement of mitochondrial dysfunction in tissue
impairment induced by these compounds.
4.1. Selective estrogen receptor modulators
Tamoxifen has been the endocrine therapy of choice for women with estrogen-receptor
positive breast carcinoma over the last decades. Fatty liver is observed in more than 30 % of
patients taking tamoxifen, which may persist after the discontinuation of the treatment [35,
36]. Nonalcoholic steatohepatitis, hepatic fibrosis, cirrhosis and hepatic necrosis were also
reported [37-39].
Tamoxifen depresses the phosphorylation efficiency and the levels of ATP in a concentration-
dependent manner in isolated rat liver mitochondria; these effects were attributed to a decrease
in the active ANT content and a partial inhibition of the phosphate carrier [40, 41]. On the other
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hand, tamoxifen uncouples liver mitochondria respiration [40, 42] and, at higher concentra‐
tions, tamoxifen disrupts membrane integrity [43-44], enhancing the proton leak [40]. Tamox‐
ifen also inhibits the electron transfer along the electron transport chain [40, 42] and the flavin
mononucleotide site of complex I was identified as the target of tamoxifen [45]. The interaction
of tamoxifen with complex III and IV was also shown [42]. The fact that tamoxifen interferes
with membrane dynamics [46] may also decrease the diffusional mobility of membrane
proteins and the electron transfer along the electron transport chain [40]. Furthermore, an in
vivo study pointed out that tamoxifen depletes hepatic mtDNA, which further contributes to
inhibit mitochondrial electron transport chain activity, and triggers steatose in mouse liver
[47]. Therefore, the effects promoted by tamoxifen on mitochondrial bioenergetics may
contribute to the liver damage observed in patients taking tamoxifen (Fig.1).
Interestingly, tamoxifen active metabolites, 4-hydroxytamoxifen and endoxifen, which are
responsible for the antitumor actions of tamoxifen [48], do not significantly compromise
mitochondrial bioenergetics at the concentrations reached in tissues [49, 50]. These results may
indicate that the clinical use of tamoxifen metabolites instead of the prodrug may minimize
liver damage. As the outcome of tamoxifen treatment seems to rely on its metabolic activation
and endoxifen is a promising drug for cancer treatment, the future utilization of tamoxifen
metabolites, and especially endoxifen, deserves further investigation. On the other hand,
tamoxifen prevents and reverses the MPT induced by several agents [51-55]. Likewise,
tamoxifen metabolites 4-hydroxytamoxifen and endoxifen also prevent and reverse the MPT
induced by calcium and phosphate [50, 56]. Although the mechanisms underlying the
inhibition of MPT by the antiestrogens are still under debate [57], this protective effect of TAM
and its active metabolites regarding MPT might be of interest when considering combined
anticancer drug therapies since it can decrease the toxicity of the associated drugs, as discussed
in section 5.
4.2. Antiandrogens
Flutamide is a nonsteroidal anti-androgen used in the treatment of advanced prostate cancer,
which has been associated with idiosyncratic drug-induced liver injury [58] and, although the
mechanisms underlying liver damage are still unknown, mitochondria are a potential target
of flutamide.
Indeed, high-doses of flutamide promote hepatocytes death in heterozygous Sod2(+/-) mice,
but not in wild-type animals, suggesting that flutamide may exacerbate underlying mitochon‐
drial abnormality [59]. Flutamide leads to the covalent binding of reactive electrophilic
metabolites to proteins and diminishes the reduced glutathione (GSH)/glutathione disulfide
(GSSG) ratio, as well as the total protein thiols in isolated rat hepatocytes; these effects are
associated with the release of lactate dehydrogenase (LDH) [60]. Similar findings were
reported by others, which also demonstrated that flutamide increases the hepatic GSSG/GSH
ratio, the protein carbonyl levels, and serum lactate levels, supporting the view that the liver
damage promoted by flutamide involves oxidative stress and mitochondrondrial dysfunction
[59]. Accordingly, the addition of cysteine increased hepatocellular GSH and decreased LDH
release in male hepatocytes [60].
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Additionally, flutamide markedly impairs rat liver mitochondrial respiration (mainly at the
level of complex I) and decreases the levels of ATP in rat hepatocytes [60]. Moreover, flutamide-
treated Sod2(+/-) mice present a decrease in the expression of complexes I and III subunits [59].
Therefore, it seems possible that the increased oxidative stress promoted by flutamide may
damage mitochondrial proteins and mtDNA, particularly when the antioxidant system is
compromised [59], contributing to liver damage (Fig.1).
4.3. Alkylating agents
4.3.1. Platinum analogs
Cisplatin, which crosslinks DNA, is widely used in the treatment of head, neck, bladder
ovarian and testicular cancers, but it has also been used in the management of other malig‐
nancies. Unfortunately, cisplatin promotes severe side effects, and particularly nephrotoxicity
[61] and neurotoxicity [62].
Peripheral neuropathy is the dose limiting side effect of cisplatin and occurs in 30 % of patients.
Dorsal root ganglion neurons treated with cisplatin exhibit mitochondrial vacuolization and
degradation both in vitro and in vivo, suggesting that mitochondrial damage is involved in
cisplatin-induced neurotoxicity (Fig.1) [63]. Besides covalently binding to nuclear DNA [64],
cisplatin also directly binds to mtDNA, hindering the transcription of mitochondrial genes
[63]. Another platinum analog, oxaliplatin, affects both complex I- and complex II-mediated
respiration and decreases ATP production in rat peripheral nerve axons [65]. Acetyl-l-
carnitine, which inhibits the development of oxaliplatin-evoked neuropathy, prevents
oxaliplatin-induced mitochondrial dysfunction, further implicating mitochondria in the
etiology of peripheral neuropathy [65].
About a quarter to one third of patients undergoing cisplatin treatment experience nephro‐
toxicity, which is manifested clinically as lower glomerular filtration rate and reduced serum
magnesium and potassium levels [61]. Although the mechanism underlying cisplatin neph‐
rotoxicity is not yet clear, the available evidence suggests that mitochondrial dysfunction plays
a key role in renal tubular cell injury and death. Ultrastructural analysis of cisplatin-treated
renal tubular cells of mouse kidney demonstrates the decrease in mitochondrial mass,
disruption of cristae, and extensive mitochondrial swelling [66], supporting the involvement
of mitochondria in cisplatin-induced nephrotoxicity. Cisplatin decreases manganese super‐
oxide dismutase and complex II activity in rodents’ kidney [67]. The GSH-reductase activity
and the levels of GSH are markedly diminished in porcine proximal tubular cells [68]. These
observations suggest that cisplatin strongly reduces the antioxidant defenses and favors ROS
formation. However, agents that are able to prevent ROS formation, do not prevent cell death,
suggesting that ROS formation is not the direct cause of cell death [68]. Furthermore, cisplatin
significantly impairs kidney mitochondrial bioenergetic functions. In porcine proximal tubular
cells, cisplatin inhibits complexes I to IV and decreases intracellular ATP [68]. In fact, the kidney
of animals treated with cisplatin presents decreased mtDNA content and reduced complex I,
III and IV protein expression [67].
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Cisplatin is a rare cause of hepatotoxicity (steatosis and cholestasis) at standard doses, but high
doses may lead to liver damage, revealed by abnormal liver tests, especially aspartate amino‐
transferase (AST) and alanine aminotransferase (ALT) [69]. Light microscopic observations
confirmed that high doses of cisplatin cause massive hepatotoxicity; alterations at the ultra‐
structural level, including atrophied mitochondria, were also found [70]. Cisplatin induces
MPT in rat liver mitochondria [71]. Moreover, cisplatin stimulates state 4 respiration, but does
not affect FCCP-uncoupled respiration, suggesting that cisplatin affects mitochondrial
bioenergetics by increasing the IMM permeability to protons and not by interfering with
respiratory chain complexes activity [71]. Both the induction of MPT and the effects on liver
mitochondrial bioenergetics are prevented by thiol group protecting agents, suggesting that
changes on the redox-status of thiol groups affect membrane permeability to cations and
underlie liver mitochondrial dysfunction [71]. Accordingly, it was proposed that the mecha‐
nism of cisplatin-induced hepatotoxicity involves membrane rigidification, lipid peroxidation,
oxidative damage of cardiolipin and protein sulfhydryl groups, as well as decreased GSH/
GSSG ratio, ATP, GSH and NADPH [72].
4.3.2. Nitrogen mustards
Cyclophosphamide is an alkylating agent used in the treatment of lymphomas, multiple
myeloma, and certain types of leukemia, retinoblastoma, neuroblastoma, ovarian cancer, and
breast cancer. Generally, cyclophosphamide does not cause relevant cardiotoxicity, but when
it occurs, it appears to be related to a single dose, unlike the anthracyclines [3]. Patients who
were previously medicated with anthracyclines or that underwent chest irradiation are more
prone to suffer from cyclophosphamide-induced cardiotoxicity [3]. Liver damage was also
reported [73, 74].
Cyclophosphamide  compromises  calcium  accumulation  by  heart  or  liver  mitochondria,
which can almost be restored by CyA [75]. As the increases in the levels of serum AST,
serum ALT, glucose-6-phosphate dehydrogenase and creatine phosphokinase induced by
cyclophosphamide can also be attenuated by the simultaneous administration of CyA, the
induction of MPT is closely related to the hepatotoxicity and cardiotoxicity promoted by
cyclophosphamide (Fig.1) [75].
Ifosfamide, another nitrogen mustard, is one of the most commonly implicated drugs in kidney
injury [76]. Using mitochondria isolated from the kidney of rats treated with ifosfamide, it was
shown that this alkylating agent significantly inhibits complex I, resulting in NADH elevation
and NAD+depletion, and Krebs cycle impairment (Fig.1) [77]. Among the ifosfamide metabo‐
lites, only chloroacetaldehyde, which reaches high concentrations in the renal cortex, inhibits
complex I, suggesting that this metabolite is responsible for the ifosfamide-induced nephro‐
toxicity [77].
4.3.3. Alkyl sulfonates
Busulfan is an alkylating drug, which forms DNA intrastrand crosslinks, used in the clinical
management of chronic myelogenous leukemia. Although in standard doses busulfan rarely
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causes liver dysfunction, some cases of hepatotoxicity during busulfan treatment were
reported [78-80].
The toxicity of busulfan is thought to involve oxidative stress mechanisms as it promotes
decreases in GSH in hepatocytes both in vivo and in vitro [81]. Considering that glutathione S-
transferase inhibitors and antioxidants prevent busulfan toxicity in vitro, it is likely that
busulfan toxicity requires glutathione conjugation [81] Moreover, the effects of busulfan are
strongly exacerbated on GSH-depleted hepatoctyes [81], which may provide a basis to explain
the enhanced sensitivity to the liver damaging effects of busulfan under certain circumstances.
4.4. Enzyme inhibitors
4.4.1. Anthracyclines
Doxorubicin is used in the clinical management of a wide range of cancers, and particularly
in breast cancer treatment. The anticancer activity of doxorubicin involves its intercalation into
DNA and disruption of topoisomerase-II-mediated DNA repair, as well as the generation of
ROS that lead to lipid peroxidation, as well as membrane and DNA damage [82]. However,
its therapeutic use is limited by its side-effects, mainly the dose-dependent myelosuppression
and the cumulative and irreversible cardiotoxicity, which in the most severe forms may lead
to patient death [83].
Acute cardiotoxicity occurs in less than 1 % of the patients immediately after infusion and is
usually reversible; the early-onset chronic progressive form affects 1.6–2.1 % of patients, during
therapy or within the first year after treatment; the late-onset chronic progressive form occurs
after one year of completion of therapy in 1.6–5 % of patients, supporting the need of long-
term follow-up [3]. Doxorubicin causes myocardial damage as shown by the increase in serum
levels of AST, ALT, LDH isoenzyme and creatine phosphokinase isoenzyme [84]. Doxorubicin-
induced cardiotoxicity etiology seems complex, and several effects may be involved, triggering
a domino effect [83]. Among the several mechanisms postulated, the induction of oxidative
stress is the most widely accepted. The univalent reduction of the tetracyclic ring of anthra‐
cycline by complex I generates a semiquinone free radical; the unpaired electron of this
semiquinone is transferred to oxygen, forming the superoxide radical, while the tetracyclic
ring returns to the parent quinone [85]. The free radicals generated are thought to be related
to the interference with calcium homeostasis and bioenergetic functions, lipid peroxidation,
and mtDNA damage, which play a key role in the pathogenesis of doxorubicin cardiotoxicity
(Fig.1).
Heart mitochondria isolated from rats treated with doxorubicin present decreased state 3
respiration and respiratory control ratio (RCR), whereas the state 4 respiration is not affected
[86-88]; complex I activity is also inhibited [87]. Besides affecting nuclear DNA, doxorubicin
damages mtDNA [89-91] and decreases its content in human hearts [90]. Accordingly,
doxorubicin-exposed human hearts show low activity of complex I and IV (encoded by
mtDNA) but not of complex II (exclusively encoded by nuclear DNA) [90]. The higher levels
of superoxide in doxorubicin-exposed hearts correlate negatively with mtDNA content and
with the activities of respiratory chain complexes encoded by mtDNA [90]. The damage
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leading to mtDNA adducts, as well as the higher rate of ROS formation and depression of GSH
in heart tissue, persist for several weeks after cessation of doxorubicin treatment [92, 93].
Furthermore, mitochondria isolated from the heart of rats treated with doxorubicin present
diminished ability to accumulate calcium [84, 86, 87, 94]. Similar effects were reported in
mitochondria isolated from doxorubicin-treated human atrial trabeculae, and were shown to
be reversed by CyA [95]. Considering that the decrease in left ventricular fractional survival
promoted by doxorubicin is improved by the simultaneous administration of CyA, it seems
that doxorubicin-induced heart damage is closely related to the induction of MPT pore opening
[84, 96]. As discussed in section 3.3, oxidative stress is a major factor regulating MPT and
doxorubicin leads to the oxidation of mitochondrial glutathione and to the accumulation of
membrane disulfides, which may contribute to MPT induction. On the other hand, it has been
proposed that the ANT is a key target for doxorubicin, as following doxorubicin treatment the
amount of ANT protein and its active content are reduced in rats [94, 97]. The effects of
doxorubicin on the ANT explain both the MPT induction and the effects on mitochondrial
respiration [97]. Indeed, the decrease in state 3 respiration observed in heart mitochondria
isolated from doxorubicin-treated rats is partially reversed by CyA or dithiothreitol, but not
by trolox, suggesting that the toxic effects of doxorubicin on mitochondrial bioenergetics are
at least in part a consequence of MPT induction and involve changes in the redox state of thiol
groups [88]. Noteworthy, among several agents, including antioxidants, CyA was the only
agent that was able to reverse the doxorubicin-induced alterations in the calcium accumulation
capacity when added ex vivo [94]. Although the triggering of MPT by doxorubicin may initially
involve the oxidation of regulatory components of the MPT pore megacomplex, once it occurs
thiol protecting agents are unable to restore the pore to its original closed state [94, 98].
Therefore, antioxidants may be useful in the preventive setting, as discussed in section 5.
Moreover, by increasing the generation of free radicals, doxorubicin also significantly enhan‐
ces lipid peroxidation, as well as alterations in proteins and biomolecules that act as signaling
molecules [99-101].
Altogether, the results obtained so far suggest that the persistent nature of doxorubicin
cardiotoxicity reflects a self-perpetuating mechanism, where mtDNA alterations accumulate,
leading to a damaged respiratory chain and decreased calcium loading ability; the defective
respiratory chain further enhances ROS generation and mtDNA insult (Fig.1) [83, 98].
The heart is the main target of doxorubicin toxicity, due to the abundance of mitochondria in
heart tissue, the elevated rate of oxygen consumption and the lower antioxidant defenses [83].
However, mitochondrial dysfunction has also been observed in other tissues. Indeed, in
isolated mitochondrial fractions from the brain of rats treated with doxorubicin, the thiobar‐
bituric acid-reactive substances and the vitamin E levels are increased, whereas the reduced
glutathione content is diminished [102]. In addition, doxorubicin increases the sensibility of
brain mitochondria to MTP pore opening [102]. The use of doxorubicin was also associated
with a higher risk for developing hepatotoxicity among breast cancer patients [103]. Liver
mitochondria isolated from doxorubicin-treated rats present decreased RCR and the activity
of complex IV is inhibited [107]. In addition, light microscopic observations confirmed that
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doxorubicin at high doses caused massive liver injury; alterations at the ultrastructural level,
such as atrophied mitochondria, were shown [70].
4.4.2. Topoisomerase inhibitors
Etoposide is a podophyllotoxin derivative used in the treatment of several cancers that acts as
a topoisomerase II inhibitor. Cases of hepatic injury were reported using either standard doses
[104] or high-dose regimens [105]. Etoposide induces calcium-dependent MPT in rat liver
mitochondria [106]. Since the etoposide-induced MPT is prevented by several antioxidants, it
was proposed that etoposide triggers MPT pore opening through the generation of oxidant
species, which is further corroborated by the ability of antioxidants to prevent the apoptosis
promoted by etoposide (Fig.1) [107]. Therefore, the generation of oxidant species that are able
to induce mitochondrial dysfunction may contribute to hepatic injury.
4.5. Antimicrotubules — Taxanes
Paclitaxel is a taxane-derived drug used in monotherapy or in combination with other agents,
for the treatment of ovarian, breast and advanced non-small cell lung cancers, and AIDS-
related Kaposi's sarcoma.
Painful peripheral neuropathy is the major dose-limiting side-effect of paclitaxel therapy, with
the major drawback that the pain and sensory abnormalities can persist for months or years.
Moreover, it may turn the patients unable to complete optimal chemotherapy schedules thus
potentially compromising the treatment efficacy [108].
The involvement of mitochondrial dysfunction in paclitaxel-induced pain is suggested by the
presence of swollen and vacuolated neuronal mitochondria [109]. Earlier investigations
demonstrated that paclitaxel promotes a CyA-sensitive swelling in liver, kidney, heart, and
brain mitochondria; the highest degree and slope of the swelling are observed in liver
mitochondria, whereas the lowest are detected in brain mitochondria [110].
Using a rat model of paclitaxel-induced pain, it was shown that the non-specific ROS scavenger
N-tert-butyl-α-phenylnitrone significantly decreases paclitaxel-induced mechanical hyper‐
sensitivity, whereas the superoxide selective scavenger 4-hydroxy-2, 2, 6, 6-tetramethylpiper‐
idine-1-oxyl (TEMPOL) does not present significant effects [108]. Therefore, the authors
suggest that ROS are involved in the development and maintenance of paclitaxel-induced pain,
although such effects cannot be attributed to superoxide radicals alone [108]. Moreover, rat
sciatic nerve samples taken after induction of painful peripheral neuropathy with paclitaxel
exhibit significant impairment of both complex I- and complex II-mediated respiration and
deficits in ATP synthesis; the mitochondrial dysfunction promoted by paclitaxel is abrogated
by acetyl-l-carnitine, again supporting that paclitaxel promotes oxidative damage [65].
Paclitaxel is extensively excreted by the liver, and therefore its administration to patients with
liver impairment should be handled with care [69]. Alterations of liver functions are seen in
4-17 % of patients treated with doses up to 190 mg/m2, but they can occur in 16-37 % of patients
taking higher doses [69].
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In isolated liver mitochondria, paclitaxel induces large amplitude swelling, the dissipation of
mitochondrial membrane potential and the release of cytochrome c; these effects are inhibited
by CyA, suggesting that paclitaxel induces MPT pore opening [110]. Paclitaxel also signifi‐
cantly increases complex IV-mediated ROS production (Fig.1) [110]. Paclitaxel does not inhibit
mitochondrial respiration, but ROS formation is abolished by complex IV inhibitors, suggest‐
ing that paclitaxel promotes ROS production not by inhibiting the respiratory complexes, but
through an effect on complex IV [110]. The abrogation of ROS formation does not prevent
paclitaxel-induced MPT, suggesting that the induction of MPT is not secondary to enhanced
ROS generation [110]. The combination with doxorubicin enhances the induction of oxidative
stress [111].
The cardiotoxicity promoted by paclitaxel is usually represented by subclinical sinus brady‐
cardia (approximately 30 % of patients), but more severe conditions were also reported [3]. A
recent study suggests that microtubule disorganization in cardiac myocytes promoted by
paclitaxel leads to MTP pore opening [112]. However, when isolated mitochondria are exposed
to paclitaxel, no significant effects are detected; the authors suggested that paclitaxel does not
promote MPT due to a direct effect on mitochondria [112]. However, it must be noted that
lower concentrations were used in the latter study in comparison with previous work using
liver mitochondria [110, 112].
Therefore, both the induction of MPT and mitochondrial ROS production can contribute to
paclitaxel side effects in the nerve, liver, kidney and heart.
4.6. Antimetabolites
4.6.1. Folate antagonists
Methotrexate is a folic acid antagonist widely used in the treatment of leukemia and other
malignancies. Gastrointestinal toxicity and liver function abnormalities are common in
patients taking methotrexate and the use of methotrexate in patients with history of liver
disease is not advisable [113].
In  liver  mitochondria,  methotrexate  promotes  a  significant  rise  in  superoxide  radical
formation, as well  as in lipid peroxidation,  whereas the GSH levels are decreased [114].
Likewise, methotrexate significantly impairs the function of isolated heart mitochondria by
promoting lipid peroxidation, mitochondrial swelling and by inhibiting complex I, II and
IV activities [115].
Methotrexate administration also leads to small intestinal injury and damages in enterocyte
mitochondria, as shown by the decrease in the RCR, an indicator of mitochondrial function
[116]. Moreover, the activities of complexes II and IV are markedly decreased in enterocyte
mitochondria, suggesting that the deleterious effects promoted by methotrexate on enterocyte
mitochondria can compromise ATP synthesis (Fig.1) [116], thereby leading to the gastrointes‐
tinal toxicity seen in patients.
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4.6.2. Purine analogs
6-Mercaptopurine is an orally administered immunosuppressive drug used to treat acute
lymphocytic leukemia. 6-Mercaptopurine is converted to its active metabolites, the 6-thiogui‐
nine nucleotides, or inactivated by xanthine oxidase or by thiopurine methyltransferase to 6-
thiouric acid or 6-methylmercaptopurine, respectively [117]. Liver injury is an important
adverse effect of 6-mercaptopurine, with an estimated frequency of liver test abnormalities
within 1-9 % range [118]. Clinically relevant concentrations of 6-mercaptopurine are toxic to
rat hepatocyte cultures by a mechanism that involves oxidative stress and ATP depletion (Fig.
1) [119]. The decreased rat hepatocytes viability promoted by 6-mercaptopurine is nearly
prevented by allopurinol (xanthine oxidase inhibitor) together with trolox (vitamin E analog),
implying xanthine oxidase-mediated metabolism of the thiopurines and oxidative stress in the
hepatotoxicity promoted by 6-mercaptopurine [119].
4.7. Retinoids
All-trans-retinoic acid was approved in 1995 by the Food and Drug Administration for the
treatment of acute promyelocytic leukemia, changing the outcome of this disease, which was
associated with a significant mortality until then. Retinoids induce hepatotoxicity, either
during dietary supplementation [120] or treatment of acute promyelocytic leukemia patients
[121], and hypertriglyceridemia [122]. Moreover, vitamin A supplementation in rats induces
slight enlargement of mitochondria [123], hepatic oxidative insult and mitochondrial dys‐
function [124], supporting the view that mitochondria are a target of retinoid toxicity.
All-trans-retinoic acid is a known inducer of MPT pore opening [125-127], which is thought to
reflect its ability to modulate ANT activity in both liver and heart mitochondria [126]. All-
trans-retinoic acid depresses the phosphorylation efficiency of mitochondria and, at higher
concentrations, induces uncoupling of mitochondria [127]. Whereas earlier studies attribute
the uncoupling promoted by retinoids to an increase in the IMM permeability [128], a more
recent study suggests that the leak of protons through the Fo fraction of complex V is the
underlying mechanism [127]. Thus, is seems likely that the liver injury promoted by all-trans-
retinoic acid reflects its effects on mitochondria (Fig.1).
4.8. Targeted therapy
4.8.1. Monoclonal antibodies
Trastuzumab is a recombinant humanized monoclonal antibody against the human epidermal
growth factor receptor 2 (HER2), which is overexpressed by many adenocarcinomas. Trastu‐
zumab improves cancer patient survival, but it also causes cardiotoxicity in a significant
number of patients, ranging from 2-7 % when used as monotherapy, 2-13 % when used
combined with paclitaxel, and up to 27 % when trastuzumab is used with both anthracyclines
and cyclophosphamide [3]. In contrast to the cardiomyopathy promoted by doxorubicin, the
cardiac dysfunction induced by trastuzumab does not appear to be dose dependent and is
often reversible [123]. Neonatal rat cardiomyocytes treated with an inhibitory HER2 antibody
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exhibit an increased ROS production and cell death, which are reversed by N-acetylcysteine
and by CyA, suggesting that the toxic effects of trastuzumab on the heart involve mitochon‐
drial damage and enhanced ROS production (Fig.1) [129].
4.8.2. Tyrosine kinase inhibitors
Sorafenib is effective against renal-cell carcinoma and hepatocellular carcinoma, whereas
sunitinib is used in the management of advanced kidney cancer, gastrointestinal stromal
tumor, and pancreatic neuroendocrine tumors. In phase I–II trials, 11 % of patients taking
sunitinib experienced cardiovascular events and approximately half of the patients developed
hypertension [130]. The incidence of sorafenib-associated heart toxicity is lower than that of
sunitinib, and hypertension occurred in about 17 % of patients in clinical trials [131].
Sorafenib compromises mitochondrial function at clinically relevant concentrations in a
myoblastic cell line grown under conditions where cells are either glycolytically or aerobically
poised; the other tyrosine kinase inhibitors investigated (imatinib, dasatinib, sunitinib) do not
affect the mitochondria [132]. Sorafenib uncouples heart mitochondria and inhibits complex
V and complex II+III; at much higher concentrations the complex I and IV are also inhibited
(Fig.1) [132].
Using neonatal rat cardiomyocyte cultures, it was shown that sunitinib decreases the mito‐
chondrial membrane potential, and that both sunitinib and sorafenib reduce the intracellular
ATP levels [133]. Echocardiographic abnormalities are apparent in sorafenib, but not in
sunitinib or pazopanib treated animals; the analysis of ventricular cardiomyocytes revealed
that sunitinib promotes mitochondrial swelling, dense deposits, and matrix cavitation,
whereas sorafenib disrupted mitochondrial cristae [133].
4.8.3. Proteasome inhibitors
Bortezomib is a proteasome-inhibitor approved for the treatment of multiple myeloma and
mantle cell lymphoma and its use in other types of cancer is currently under investigation.
However, bortezomib induces dose-limiting peripheral neuropathy and compromises
complex I- and complex II-mediated respiration, as well as ATP production in peripheral nerve
axons, suggesting that mitochondrial dysfunction plays a key role in bortezomib-induced
peripheral neuropathy (Fig.1) [134].
Mechanism Drug class Target organ References
MPT
MPT induction
All-trans-retinoic acid Miscellaneous agents Heart and liver [125-127]
Paclitaxel Antimicrotubules Heart, liver, kidney [110]
Doxorubicin Enzyme inhibitors Heart and brain [84, 86, 87, 94, 95, 102]
Etoposide Enzyme inhibitors Liver [106]
Cisplatin Alkylating agents Liver [71]
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Mechanism Drug class Target organ References
Cyclophosphamide Alkylating agents Heart and liver [75]
MPT inhibition
Tamoxifen SERMs Liver [51-55]
Mitochondrial bioenergetics
Tamoxifen SERMs Liver [40, 41, 159]
Flutamide Antiandrogens Liver [59, 60]
All-trans-retinoic acid Miscellaneous agents Liver [127]
Cisplatin Alkylating agents Liver and kidney [67, 68, 71]
Oxaliplatin Alkylating agents Nerve [65]
6-Mercaptopurine Antimetabolite Liver [119]
Ifosfamide Alkylating agents Kidney [77]
Methotrexate Antimetabolites Heart and GI [115, 116]
Paclitaxel Antimicrotubules Nerve [65]
Doxorubicin Enzyme inhibitors Heart and liver [86-88]
Sorafenib Targeted Therapy Heart [132, 133]
Sunitinib Targeted Therapy Heart [133]
Bortezomib Targeted therapy Nerve [134]
mtDNA damage
Tamoxifen SERMs Liver [47]
Cisplatin Alkylating agents Neurons and kidney [63, 67]
Doxorubicin Enzyme inhibitors Heart [89-91]
Oxidative stress
Flutamide Antiandrogens Liver [59, 60]
Doxorubicin Enzyme inhibitors Heart and brain [85, 102]
Paclitaxel Antimicrotubules Liver and nerve [108, 110]
6-Mercaptopurine Antimetabolites Liver [119]
Busulfan Alkylating agents Liver [81]
Cisplatin Alkylating agents Kidney and liver [67, 68, 72]
Methotrexate Antimetabolites Heart and liver [114, 115]
Trastuzumab Targeted therapy Heart [129]
Table 1. Summary of the mechanisms of mitochondrial dysfunction promoted by anticancer agents (GI,
gastrointestinal tract; MPT, mitochondrial permeability transition; mtDNA, mitochondrial DNA; SERMs, selective
estrogen receptors modulators).
5. A mitochondrial basis for anticancer drugs combinations: a promising
approach to therapy
The severe toxicity promoted by anticancer agents represents a substantial health care burden
that may seriously affect the treatment outcome. Based on the previous sections, mitochondria
take center stage within the toxicity mechanisms, and are in the first line for protection by
Mitochondrial Dysfunction on the Toxic Effects of Anticancer Agents— From Lab Bench to Bedside
http://dx.doi.org/10.5772/59488
39
pharmacological strategies aiming to avoid alterations that may prove deleterious both in the
short and in the long term. Considering that some of these effects are irreversible or cumulative,
it is desirable to prevent these events when planning the therapy of cancer patients.
As discussed in the previous section, oxidative stress has been established as one of the primary
cause of mitochondrial dysfunction and toxicity induced by anticancer agents and, therefore,
several antioxidants have been tested in vitro and in vivo as a prophylactic measure. In
particular, naturally occurring antioxidants have been investigated as therapeutic adjuvants,
as they are considered safe and well-tolerated, and may afford protection against cancer
treatment-related toxicity by improving mitochondrial functions.
Alpha-lipoic acid affords protection against  the neurotoxic  effects  promoted by cisplatin
and paclitaxel  through its  antioxidant and mitochondrial  regulatory functions [135].  The
toxic effects promoted by cisplatin on rat liver mitochondria are also prevented by thiol
group protecting agents [71].  Curcumin, which has anti-inflammatory and anticancerous
properties, counteracts the mitochondrial lipid peroxidation and GSH levels alterations in
mitochondria isolated from the brain and liver of rats treated with cisplatin, suggesting that
it can abrogate the toxic effects of cisplatin on brain and liver [136]. Likewise, epicatechin
prevents  the  renal  damage  and  mitochondrial  dysfunction  promoted  by  cisplatin  by
decreasing oxidative stress;  noteworthy,  epicatechin does not compromise the antitumor
actions of cisplatin in HeLa cells [67].
The etoposide-induced MPT is prevented by ascorbate, the primary reductant of the phenoxyl
radicals generated by etoposide, and by thiol protecting agents [107].
An in vitro study demonstrated that Vitamin E decreases the oxidative stress induced by
methotrexate in rat heart mitochondria and thereby minimizes mitochondrial dysfunction
[115]. Likewise, the administration of lipoic acid decreases oxidative stress induced by
methotrexate, which affects liver mitochondrial function [114].
Acetyl-L-carnitine completely blocks the effects of bortezomib on mitochondria and pain [134].
Strategies to prevent doxorubicin-induced cardiotoxicity are probably the best studied, given
the significant number of patients affected and the impact on the overall success of the
treatment. Many studies reported that antioxidants could afford cardioprotection against
doxorubicin therapy. The broad antioxidant resveratrol markedly ameliorates the cardiac
dysfunction promoted by doxorubicin, while the ROS generation is decreased, and gluta‐
thione, superoxide dismutase and catalase activities are improved [137]. Also, flavonoids, and
particularly 7-monohydroxyethylrutoside, protect against the cardiac toxic effects promoted
by doxorubicin both in vitro and in vivo [138]. In addition, 7-monohydroxyethylrutoside does
not compromise the antitumor activity of doxorubicin in human ovarian cell lines and in the
corresponding mouse xenograft models, and even inhibits the overexpression of adhesion
molecules promoted by doxorubicin on vascular endothelial cells [138]. The combination of
doxorubicin and vitamin E-succinate cooperates to induce apoptosis in human gastric cancer
cells, by promoting doxorubicin influx and suppressing its efflux [139]. On the other hand,
vitamin E also aggravates the heart damage promoted by doxorubicin in P388 tumor-bearing
mice [140].
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Studies in animals demonstrated that the inhibition of mitochondrial respiration and the
decrease in mitochondrial calcium accumulation capacity promoted by doxorubicin are
prevented by the coadministration of the beta-adrenergic receptor antagonist carvedilol [87].
The prophylactic use of carvedilol in patients receiving doxorubicin contributes to maintain
left ventricle diameters constant and to preserve diastolic function [141]. Interestingly, the toxic
effects promoted by doxorubicin on heart mitochondria and cardiac cell apoptosis are
prevented by carvedilol, but not by atenolol, another beta-adrenergic receptor antagonist with
no antioxidant action, suggesting that the antioxidant properties and not the beta-adrenergic
receptor antagonism are responsible for the cardioprotective effects of carvedilol [142].
Likewise, metoprolol, which also has no antioxidative properties, failes to afford cardiopro‐
tection in lymphoma patients treated with doxorubicin [143].
Dexrazoxane, a well-studied therapeutic adjuvant for doxorubicin chemotherapy, is a free
radical scavenger that was found to have cardioprotective effects by preventing the functional
damage of cardiac mitochondria initiated by ROS [83, 144]. Dexrazoxane prevents or reduces
cardiac injury in doxorubicin-treated children with acute lymphoblastic leukemia without
affecting the antitumor activity of doxorubicin [145]. In contrast, other iron chelators have
failed to afford the same degree of cardioprotection, suggesting that iron does not play a crucial
role in the oxidative stress-mediated toxicity of doxorubicin [138, 146, 147].
Promising results were obtained when the potent phosphodiesterase-5 inhibitor sildenafil is
combined with doxorubicin. Prophylactic treatment with sildenafil prevents cardiomyocyte
apoptosis and left ventricular dysfunction in a mouse chronic model of doxorubicin-induced
cardiotoxicity [148]. On the other hand, in breast cancer cells, sildenafil enhances sensitivity
to doxorubicin without enhancing its toxicity in bone marrow cells or macrophages [149].
Furthermore, cotreatment with sildenafil enhances doxorubicin-induced apoptosis in prostate
cancer cells and inhibits tumor growth in mice bearing prostate tumor xenografts, while
attenuating left ventricular dysfunction promoted by doxorubicin [150].
Interesting results were also observed when retinoids and antiestrogens are combined.
Antiestrogenic compounds inhibit the MPT-induced by retinoids in isolated liver mitochon‐
dria [127, 151, 152]. Noteworthy, the prevention of MPT by antiestrogens does not compromise
the antitumor efficacy of all-trans-retinoic acid, as an additive/synergistic action was demon‐
strated in breast cancer [153-156] and melanoma [157] cell lines. Therefore, we propose that
studies in vivo with combined therapies are now required to confirm that these results obtained
in vitro will translate into more therapeutic benefits in humans while attenuate mitochondrial
dysfunctions promoted by drugs used individually.
6. Concluding remarks
Considering the key role played by mitochondria in cell survival and death, the pharmaco‐
logical modulation of mitochondrial activity has been investigated in cancer therapy [13, 158].
It is thought that this strategy may overcome the resistance mechanisms related with conven‐
tional chemotherapy that do not target mitochondria directly, but interfere with signaling
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pathways which lie upstream of mitochondria and that are frequently deregulated in cancer
[158]. However, the targeting of mitochondria as a therapeutic strategy is often compromised
by the absence of significant pathophysiological differences between mitochondria in normal
and malignant cells, leading to reduced selectivity of drugs targeting mitochondria. Therefore,
the actions that are beneficial in cancer cells may, in contrast, underlie some of the severe toxic
effects promoted by these agents.
Indeed, the induction of mitochondrial damage is an important contributor for some of the
most well-known toxic effects of anticancer agents, namely the liver injury promoted by
tamoxifen [159], the cardiotoxicity of doxorubicin or the cisplatin-induced neuropathy and
nephrotoxicity. Organ dysfunction has a significant impact on the treatment outcomes and,
therefore, the better understanding of the mechanisms of toxicity may unveil strategies to limit,
or preferably to prevent, the incidence of these events and thereby improve the overall clinical
success.
The recognition that mitochondrial dysfunction plays a key role in drug-induced toxicity may
contribute to identify the drugs that are more likely to lead to such effects at an early stage. In
this context, the use of isolated mitochondria fractions is a valuable tool to predict drug safety,
since it provides relevant information while allowing to reduce the number of laboratory
animals and the costs of preclinical studies [8].
On the other hand, our current knowledge does not allow to predict the idiosyncratic injury
related with drug-induced mitochondrial dysfunction. It seems that genetic, metabolic and
environmental factors that impair mitochondrial function can add their effects to those of
anticancer drugs, compromising mitochondrial function to an extent where manifestations
start to occur [17]. Therefore, therapeutic drug monitoring is mandatory. Furthermore, as
organ damage may become apparent months or even years after the completion of the
treatment (e.g. late-onset doxorubicin toxicity) the need of long-term follow-up is reinforced.
Finally, future studies should aim to develop strategies which are able to afford protection
against both the short-term and long-term effects of anticancer drugs and without compro‐
mising their antitumor activity. Although antioxidants showed promise in in vitro studies,
inconsistent results and failure in clinical trials turn the use of antioxidants as adjuvants in
cancer therapy hardly consensual [7, 83]. However, in this context, we need to take into
consideration that antioxidants may present different intracellular localization patterns and
interfere with normal redox signaling pathways in specific cell compartments; an approach
involving the targeted delivery of antioxidants to mitochondria can possibly provide better
outcomes [7, 83]. Moreover, there are important differences between in vitro and in vivo
toxicities and between animal models and humans. The different drug metabolism and
clearance, as well as the asymmetries in redox regulation may account for the difficulty in
translating these strategies into human subjects [83].
In conclusion, studies in suitable animal models are vital for a better understanding of the
mechanisms underlying drug toxicity and the benefits of strategies aiming to prevent mito‐
chondrial damage. So far most studies have used animal models devoid of tumors, which add
an extra physiological burden that may influence the effects of drugs [83]. Moreover, as
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described in the previous section, some of the toxic effects on mitochondria are observed in
several organs, including the liver and kidneys, which may compromise both the pharmaco‐
kinetics and the efficacy of the anticancer drugs, but also the benefit of therapeutic adjuvants
aiming to protect the mitochondria. These observations emphasize the importance of per‐
forming in vivo studies in relevant models, as well as the crucial importance of the clinical
control and therapeutic drug monitoring of patients treated with anticancer drugs.
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